Skip to main content

Tocilizumab Induces and Maintains Remission in Giant Cell Arteritis

Lancet has reported the results of a randomized, double-blind, placebo-controlled trial of tocilizumab in patients with new-onset giant cell arteritis (GCA). Thirty patients were randomized (2:1) to receive either tocilizumab (8 mg/kg) or placebo intravenously every 4 weeks for a year. All patients were initially treated with high-dose prednisolone (1 mg/kg/day) and weaned off using a standardized dose-reduction scheme.

Complete remission at week 12 was achieved in 17 (85%) of 20 patients given tocilizumab and four (40%) of 10 patients given placebo (p=0·03). Relapse-free survival was achieved in 17 (85%) patients in the tocilizumab group and two (20%) in the placebo group by week 52 (p=0·001).

Patients on TCZ were more likely to stop glucocorticoids at 12 weeks and had a lower cumulative prednisolone dose (43 mg/kg) compared to those on placebo (110 mg/kg) after 52 weeks of study. 

Serious adverse events were frequent in both groups (35% for TCZ and 50% for PBO) and were largely related to high dose steroids.

This is the first randomized trial do demonstrate the induction and remission efficacy of IL-6 inhibition with tocilizumab in patients with giant cell arteritis.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject